USask researchers seek to prevent liver disease, high blood pressure, and understand lifelong impacts of Zika virus
Three University of Saskatchewan researchers have been awarded a total of $1.87 million by the Canadian Institutes for Health Research (CIHR) for projects involving fatty liver disease, high blood pressure, and Zika virus.
Canada’s Global Nexus and VIDO join forces to combat COVID–19
Canada’s Global Nexus for Pandemics and Biological Threats at McMaster University and VIDO at USask are working together to accelerate vaccine and drug development, human clinical trials and create new diagnostic tools.
VIDO gains provincial support towards becoming a ‘Centre for Pandemic Research’
The Government of Saskatchewan committed $15 million to support the University of Saskatchewan’s Vaccine and Infectious Disease Organization’s position as a Centre for Pandemic Research.
USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV
The first volunteers have been selected for a vaccine trial of COVAC-2, a COVID-19 vaccine developed by the Vaccine and infectious Disease Organization at the University of Saskatchewan.
New support to produce COVID-19 vaccines and treatments in Canada
Prime Minister Justin Trudeau's announcement regarding new support to produce #COVID19 vaccines and treatments in Canada:
USask livestock research receives significant investment to advance industry
Saskatchewan’s Agriculture Development Fund will provide more than $6.5 million to support livestock research efforts at USask including $1.58 million for VIDO.
A new year, and a new look
With a refreshed recognition of our history and in celebration of our future, we recently embraced a new, enhanced visual identity that symbolizes our national and international impact.